Compare · INVA vs TBPH
INVA vs TBPH
Side-by-side comparison of Innoviva Inc. (INVA) and Theravance Biopharma Inc. (TBPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INVA and TBPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- INVA is the larger of the two at $1.60B, about 1.8x TBPH ($872.8M).
- Over the past year, INVA is up 11.4% and TBPH is up 49.6% - TBPH leads by 38.1 points.
- TBPH has hit the wire 6 times in the past 4 weeks while INVA has been quiet.
- TBPH has more recent analyst coverage (23 ratings vs 10 for INVA).
- Company
- Innoviva Inc.
- Theravance Biopharma Inc.
- Price
- $21.73-2.23%
- $16.93-0.29%
- Market cap
- $1.60B
- $872.8M
- 1M return
- -3.94%
- +1.38%
- 1Y return
- +11.41%
- +49.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- News (4w)
- 0
- 6
- Recent ratings
- 10
- 23
Innoviva Inc.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Theravance Biopharma Inc.
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Latest INVA
- Nortiva Bio Launches to Develop Long-Acting Oral Medicines
- Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
- Innoviva to Participate in Upcoming Investor Conferences
- Chief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares and was granted 1,123 shares, decreasing direct ownership by 0.00% to 285,929 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Basso Stephen was granted 1,123 shares and covered exercise/tax liability with 559 shares, increasing direct ownership by 0.64% to 88,571 units (SEC Form 4) to satisfy withholding tax
- Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 57,516 units (SEC Form 4) (for withholding tax)
- Director Linden Josephine was granted 15,194 shares (SEC Form 4)
- New insider Linden Josephine claimed no ownership of stock in the company (SEC Form 3)
- SEC Form 8-K filed by Innoviva Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Innoviva Inc.
Latest TBPH
- SEC Form 4 filed by Theravance Biopharma Inc.
- Large owner Samaha Eli sold $5,791,555 worth of COM (336,697 units at $17.20) (SEC Form 4)
- SEC Form DEFA14A filed by Theravance Biopharma Inc.
- Theravance Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
- Zymeworks to Acquire Theravance Biopharma, Inc.
- SVP, DEV & HEAD OF IRE OFFICE Miller Aine was granted 18,750 units of Ordinary Shares, increasing direct ownership by 11% to 196,084 units (SEC Form 4)
- Theravance Biopharma Inc. filed SEC Form 8-K: Leadership Update
- SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $218,167 worth of Ordinary Shares (13,314 units at $16.39) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 232,457 units (SEC Form 4)
- Director Smaldone Alsup Laurie was granted 6,009 units of Ordinary Shares, increasing direct ownership by 8% to 80,989 units (SEC Form 4)